2012 © Institute for Molecular Medicine Finland FIMM
Principal Investigator Heli Nevanlinna
Primary Affiliation: Helsinki University Central Hospital
Heli Nevanlinna's research project "Novel genes and gene interactions in breast cancer risk and progression" focuses on identification of genes that may modify the risk effect of the breast cancer susceptibility genes BRCA1, BRCA2 or CHEK2, or that may have an effect on tumour progression and patient survival. The project uses in vitro functional approaches (DNA break repair) in mutation carrier cells for identification of genes related to these pathways as well as targeted siRNA analyses of candidate genes. The project will reveal molecular mechanisms for breast cancer susceptibility and progression and has also clinical signifi-cance for more accurate evaluation of breast cancer risks associated with BRCA1 and BRCA2 as well as CHEK2 mutations at individual level or with specific subgroups of patients.
Heli Nevanlinna
Department of Obstetrics and Gynecology
Helsinki University Central Hospital
Biomedicum Helsinki 4th floor
P.O. BOX 700
00029 HUS
Finland
Tel. +358 9 4717 1750
Fax +358 9 4717 1751
heli.nevanlinna@hus.fi